

Date: December 12, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza, C – 1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

SYMBOL: REMUS

Sub: Clarification to e-mail dated December 07, 2024
Reference: Exchange e-mail dated December 07, 2024

Dear Sir/Madam,

We hereby acknowledge the receipt of your e-mail dated December 07, 2024, wherein the exchange has sought clarifications with respect to the Financial Results submitted by us on November 09, 2024 for the half year ended September 30, 2024. In respect of which we hereby submit below clarification/justification in seriatim:

We submit that:

1. The company have prepared and submitted the financial results for the half year ended September 30, 2024 along with the Limited Review Report (“Financial Results”) in compliance with the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 13, 2023;
2. Further, in compliance with the circulars issued by the exchange from time to time the Company had submitted the Machine-Readable / Legible copy of Financial Results, however, upon receipt of aforesaid e-mail from exchange we found that inadvertently certain pages were not in Machine Readable Form, in order to set the documents right the Company has re-uploaded the said Financial Results for the for the half year ended September 30, 2024. A copy of the acknowledgement for submission of the same is enclosed herewith as **Annexure- A**;
3. Furthermore, a copy of the certificate for utilization of issue proceeds by the Company duly signed by the auditor as per NSE circular dated September 05, 2024 NSE/CML/2024/23 is attached herewith as **Annexure- B**. We also, undertake that we will continue to submit the aforesaid certificate until the issue proceeds are fully utilized or the purpose for which the proceeds were raised are fulfilled; and
4. Furthermore, the Company has incorporated a subsidiary in Guatemala in name and style of “Relius Pharma LTDA”. As, the Company is yet to infuse the capital in the said Subsidiary, hence, the company has not consolidated the financials of the said subsidiary in the said Financial Results. As responsible corporate entity, we have also disclosed the said information by way of note no. 8 to the Consolidated Financial Results in order to provide true and correct information to the stakeholders of the company.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

We request the exchange to consider our above submissions and at the same time we also hereby undertake to take due care while making submissions to the exchange in future.

**Thanking you
Yours Sincerely,
For, Remus Pharmaceuticals Limited**

**Deval Patel
Company Secretary & Compliance Officer
Membership No.: A60090**

Encl.: As Above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536



National Stock Exchange Of India Limited

Date of 12-Dec-2024

NSE Acknowledgement

Symbol:-	REMUS
Name of the Company: -	Remus Pharmaceuticals Limited
Submission Type:-	Announcements
Short Description:-	Updates
Date of Submission:-	12-Dec-2024 06:52:17 PM
NEAPS App. No:-	2024/Dec/5166/5192

Disclaimer : We hereby acknowledge receipt of your submission through NEAPS. Please note that the content and information provided is pending to be verified by NSEIL.

Pankaj R Shah & Associates

Chartered Accountants

CA. DR. Pankaj Shah CA. Chintan Shah CA. Nilesh Shah CA. Manali Shah CA. Sandip Gupta
B.Com., F.C.A., Ph. D. (Commerce) B.Com., L.L.B., F.C.A. B.Com., L.L.B., F.C.A. B.Com., F.C.A. B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : <http://www.prsca.in>

CERTIFICATE

We, Pankaj R Shah & Associates, Chartered Accountants, Statutory Auditors of Remus Pharmaceuticals Limited, having its registered office situated at 1101 to 1103 South Tower One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad - 380054 Gujarat, certify that Remus Pharmaceuticals Limited has utilized the funds raised through Initial Public Offer (IPO) up to 30th September, 2024, as under :

Utilization of Funds up to on 30.09.2024			(Amount in Rs Lakhs)	
Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Unutilised Amount	Remarks
Public Issue Expenses	100.00	100.00	-	
To Meet Working Capital Requirements	3030.36	2480.36	550.00	Fixed Deposit available in HDFC bank
Funding Investment for acquisition and General Corporate Purpose	1,638.16	1,638.16	-	
TOTAL	4,768.52	4218.52	550.00	

The above details are given on the basis of necessary records & books of accounts produced before us and information given to us.

On the basis of details submitted before us and also on the basis of management representation received and also on the basis of the Prospectus, we hereby certify that up to 30th September, 2024, there are no deviation/variation in utilization of funds for which the same have been raised.

For, Pankaj R Shah & Associates
Chartered Accountants
Firm Reg. No. – 107361W

N. R. Shah
CA Nilesh Shah
Partner
Membership No. 107414
UDIN: 24107414BJZYKY8129
Place: Ahmedabad
Date: 09/11/2024

